CFRA Downgrades Novo Nordisk (NVO) to Sell
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mail
Get Alerts NVO Hot Sheet
Price: $39.06 -0.74%
Rating Summary:
8 Buy, 16 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 31
Rating Summary:
8 Buy, 16 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 31
Join SI Premium – FREE
CFRA analyst Wan Nurhayati downgraded Novo Nordisk (NYSE: NVO) from Hold to Sell with a price target of $38.00.
For an analyst ratings summary and ratings history on Novo Nordisk click here. For more ratings news on Novo Nordisk click here.
Shares of Novo Nordisk closed at $39.80 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Abbott Labs (ABT) PT Lowered to $125 at BTIG
- Goldman Sachs on Meta Platforms Inc. (META): 'We expect investors to have an initial positive reaction'
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
Create E-mail Alert Related Categories
DowngradesRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
